Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients

International Journal of Clinical Practice

Volumn 59, Issue 4, 2005, Pages 478-484

  Robles, Nicolás R ^a   Martin Aguenda B ^b   Lez Munoz F ^c   Alamo C ^c   Cantero del Rio I ^d   Acosta Mendez J M ^d   Royo del Rio Royo M ^d   Martin Suarez D A ^d   Dominguez Afonso J C ^d   Montanes Rustullet J C ^d   Moro Mateos, M L ^d   Freire Corzo, J ^d   Gonzalez L M ^d   Prieto Diaz M A ^d   Aparici Feal, M ^d   Santamaria J L ^d   Rosello F J ^d   Barreda Gonzalez M J ^d   Razquin Medina A ^d   Hernandez Rodriquez F ^d   Perez de Mendiguren Ruiz de Olallo, I ^d   Alkorta Isasti, L ^d   Domenech Delgado J ^d   Fernandez Fresnedo G ^d   Alkassam Mukdise, A ^d   Cuadrillero Garcia I ^d   Pacheco Sarabia, R ^d   Gasull Molinera, V ^d   Aliaga Estelles, V P ^d   Soler David, V ^d   Martinez Perez J L ^d   Iranzo Simio C ^d   Martin Clos J ^d   Moreno Puertas, C ^d   Castillo Duran M I ^d   Carretero, J F ^d   Gutierrez Aparicio G ^d   Orozco Gonzalez F ^d   Esparza Salcedo, J A ^d   Aliaga Martin A ^d   Aboin Mohd, H ^d   Franch Nadal, J ^d   Pare Canals, A ^d   Delgado Prieto, J L ^d   Maranes Antonanzas A ^d   Molina Molina, F ^d   Gomez Soler F ^d   Liebana Canada A ^d   Navas Navas, C ^d   Saavedra Pita, F ^d   Olivas Garcia E ^d   Palomar Marin A ^d   Duran Dotres F ^d   Garcia Alegria T ^d   Pinero Marin A ^d   Luquin Martinez R ^d   Peris Velarde, J M ^d   Navarro Macia M C ^d   Infante Redondo, J ^d   Jimenez Perez J L ^d   Castro Torres, A ^d   Ramirez Nuno J A ^d   Hidalgo Santiago, J C ^d   Galan Bernal A ^d   Aboudan Mulaines, N ^d   Moron Rubio A ^d   Gimenez Velez J I ^d   Hinojosa Gallardo, J L ^d   Corzo Ballester, J F ^d   Martinez Prieto E N ^d   Calderon Vega J ^d   Martinez Garcia J M ^d   Ruiz Munoz L M ^d   Cordoba Garcia R ^d   Catalan Ramos J I ^d   Caraballo Espana L G ^d   Tenorio Herrero, I ^d   Garcia Mateos F ^d   Vergara Hernandez J ^d   Garcia Gallego F ^d   Velazquez Arias E ^d   Utrilla Mainz, V ^d   Barhoum Georgeos, G ^d   Benitez Arroyo A ^d   Arribas Aguirregaviaria, F J ^d   Salamanca Romero, F J ^d   Matamala Sacristan J ^d   Plana Rodrigeuez J ^d   Martin Corominola A ^d   Castella Cahiz, S ^d   Banchs Galtes L ^d   Rodriguez Avila Z ^d   Lopez Rodriguez C ^d   Fernandez Cuadrillero C ^d   Aparicio Loran A ^d   Alfaro Lozano, A ^d   Ferreras Gonzalez P ^d   Morala Morala, J ^d   Mayo Silva, F ^d   Rodriguez Poncelas A ^d   Fernandez Ubach M ^d   Garcia Rosello J M ^d   Hernndez Redondo P ^d   more..

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

^d NONE

Author keywords

Eprosartan; Hypertension; Pulse pressure

Indexed keywords

DOXAZOSIN; EPROSARTAN;

ADULT; AGED; ANEMIA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; ESSENTIAL HYPERTENSION; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATEMESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; VOMITING;

ACRYLATES; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULSE; THIOPHENES; TREATMENT OUTCOME;

EID: 20144389289     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00515.x     Document Type: Article

References (22)

1. Van Bortel LM, Struijker-Boudier HA, Safir ME. Pulse pressure, arterial stiffness, and drug treatment of hypertension. Hypertension 2001; 38: 914-21.
2. Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med 1993; 329: 1912-7.
3. Franklin SS, Khan SA, Wong ND et al. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation 1999; 100: 354-60.
4. Benetos A, Zureik M, Morcet J et al. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol 2000; 35: 673-80.
5. Macia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20 1461-4.
6. Sega R. Efficacy and safety of eprosartan in severe hypertension, Eprosartan Multinational Study Group. Blood Press 1999; 8: 114-21.
7. De la Sierra A, Muñoz A, Arcos E et al. Efecto del tratamiento con eprosartan sobre la presión de pulse. Factores predictores de respuesta [Artice Spanish]. Hipertensión 2003; 20: 56-62.
8. The sixth report of the Joint National Committee on prevention, detection evaluation and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-46.
9. Cocchi R, Degli Esposti E, Ruffo P et al. Cardiovascular risk in hypertensive patients: results of the Pandora project. J Nephrol 2002; 15: 29-35.
10. McInnes GT. Angiotensin II antagonists in systolic blood pressure control. Hosp Med 2001; 62: 773-7.
11. Riulope L, Jäger B. Eprosartan for the treatment of hypertension. Expert Opin Pharmacother 2003; 4: 107-14.
12. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
13. Okin PM, Devereux RB, Jern S et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study. Circulation 2003; 108: 684-90.
14. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
15. Kjeldsen SE, Dahlof B, Devereux RB et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491-8.
16. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349 1893-906.
17. Gradman AH, Gray J, Maggiacomo F et al. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group. Clin Ther 1999; 17: 129-36.
18. Gavras I, Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin 1999; 15: 15-24.
19. Hedner T, Himmelmann A. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group. J Hypertens 1999; 17: 129-36.
20. Sachse A, Verboom CN, Jager B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens 2002; 16: 169-76.
21. Punzi HA, Punzi CF. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. J Hum Hypertens 2004; 18: 655-61.
22. Puig JG, Lopez MA, Bueso TS et al. Clinical profile of eprosartan. Cardiovasc Drug Ther 2002; 16: 543-9.